OTCMKTS:GNMSF - Genmab As Stock Price, Price Target & More

$209.50 0.00 (0.00 %)

(As of 04/22/2018 02:35 AM ET)

Previous Close$209.50

Today's Range$209.50 - $209.50

52-Week Range$163.00 - $239.75

Volume788 shs

Average Volume180 shs

Market Capitalization$12.84 billion

P/E Ratio73.25

Dividend YieldN/A

Beta0.55

About Genmab As (OTCMKTS:GNMSF)

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM). Its products under development include Ofatumumab to treat CLL and follicular lymphoma; Ofatumumab (OMB157) for relapsing remitting multiple sclerosis; and Daratumumab to treat MM, Non-Hodgkin's lymphoma, and solid tumors, as well as natural killer/T-cell lymphoma, nasal type. The companys products under development also comprise Tisotumab vedotin for treating solid cancers; HuMax-AXL-ADC for solid cancers; Teprotumumab for the treatment of Graves' orbitopathy; AMG 714 for celiac disease; ADCT-301 (HuMax-TAC-ADC) to treat lymphoma and acute myeloid leukemia (AML) or acute lymphoblastic leukemia; JNJ-61186372 for non-small-cell lung cancer; and NJ-63709178 for the treatment of AML. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company was founded in 1999 and is based in Copenhagen, Denmark.

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolOTCMKTS:GNMSF

CUSIPN/A

Webwww.genmab.com

Phone45-7020-2728

Debt

Debt-to-Equity RatioN/A

Current Ratio13.04%

Quick Ratio13.04%

Price-To-Earnings

Trailing P/E Ratio73.25

Forward P/E Ratio80.27

P/E GrowthN/A

Sales & Book Value

Annual Sales$269.88 million

Price / Sales47.57

Cash Flow$2.9227 per share

Price / Cash71.68

Book Value$11.89 per share

Price / Book17.62

Profitability

EPS (Most Recent Fiscal Year)$2.86

Net Income$176.39 million

Net Margins50.30%

Return on Equity21.78%

Return on Assets20.01%

Miscellaneous

Employees205

Outstanding Shares61,280,000

How to Become a New Pot Stock Millionaire

Genmab As (OTCMKTS:GNMSF) Frequently Asked Questions

What is Genmab As' stock symbol?

Genmab As trades on the OTCMKTS under the ticker symbol "GNMSF."

How were Genmab As' earnings last quarter?

Genmab As (OTCMKTS:GNMSF) released its earnings results on Wednesday, November, 5th. The company reported $0.47 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.45 by $0.02. The company earned $45.65 million during the quarter, compared to analysts' expectations of $53.94 million. Genmab As had a net margin of 50.30% and a return on equity of 21.78%. View Genmab As' Earnings History.

When is Genmab As' next earnings date?

Genmab As is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Genmab As.

Who are some of Genmab As' key competitors?

Some companies that are related to Genmab As include Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Nektar Therapeutics (NKTR), Grifols (GRFS), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), SAGE Therapeutics (SAGE), Alkermes (ALKS), Valeant Pharmaceuticals International (VRX), Ionis Pharmaceuticals (IONS), Catalent (CTLT) and Dr. Reddy's Laboratories (RDY).

Has Genmab As been receiving favorable news coverage?

Media stories about GNMSF stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genmab As earned a media sentiment score of 0.20 on Accern's scale. They also assigned news stories about the company an impact score of 45.85 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Genmab As?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genmab As' stock price today?

One share of GNMSF stock can currently be purchased for approximately $209.50.

How big of a company is Genmab As?

Genmab As has a market capitalization of $12.84 billion and generates $269.88 million in revenue each year. The company earns $176.39 million in net income (profit) each year or $2.86 on an earnings per share basis. Genmab As employs 205 workers across the globe.

How can I contact Genmab As?

Genmab As' mailing address is BREDGADE 34E, COPENHAGEN G7, . The company can be reached via phone at 45-7020-2728 or via email at [email protected]

MarketBeat Community Rating for Genmab As (GNMSF)

Community Ranking:		1.8 out of 5 ()
Outperform Votes:		68 (Vote Outperform)
Underperform Votes:		118 (Vote Underperform)
Total Votes:		186

MarketBeat's community ratings are surveys of what our community members think about Genmab As and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Genmab As (OTCMKTS:GNMSF) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Genmab As in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.00	2.00	2.00	2.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Genmab As (OTCMKTS:GNMSF) Consensus Price Target History

Price Target History for Genmab As (OTCMKTS:GNMSF)

Genmab As (OTCMKTS:GNMSF) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Details
10/6/2017	JPMorgan Chase	Downgrade	Overweight -> Neutral
4/4/2017	Deutsche Bank	Downgrade	Buy -> Hold

(Data available from 4/22/2016 forward)

Genmab As (OTCMKTS:GNMSF) Earnings History and Estimates Chart

Earnings by Quarter for Genmab As (OTCMKTS:GNMSF)

Genmab As (OTCMKTS:GNMSF) Earnings Estimates

2018 EPS Consensus Estimate: $3.70

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.72	$0.72	$0.72
Q2 2018	1	$0.13	$0.13	$0.13
Q3 2018	1	$2.12	$2.12	$2.12
Q4 2018	1	$0.73	$0.73	$0.73

Genmab As (OTCMKTS GNMSF) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018
11/8/2017	Q3 2017		($0.01)		$51.08 million	View	N/A
8/9/2017	Q2 2017		$0.73		$114.26 million	View	N/A
5/10/2017	Q1 2017		$0.04	$35.19 million	$35.93 million	View	N/A
3/28/2017	Q4 2016		$1.98		$134.64 million	View	N/A
11/2/2016	Q3 2016		$0.46		$54.70 million	View	N/A
8/9/2016	Q2 2016	$0.24	$0.41	$49.68 million	$53.72 million	View	N/A
5/10/2016	Q1 2016	($0.25)	($0.03)	$10.31 million	$25.15 million	View	N/A
2/17/2016	Q4 2015		$0.95		$84.32 million	View	N/A
11/3/2015	Q3 2015		$0.34		$41.41 million	View	N/A
8/11/2015	Q2 2015	$0.44	$0.04	$47.57 million	$25.76 million	View	N/A
5/12/2015	Q1 2015		$0.55		$16.19 million	View	N/A
11/5/2014	Q3 2014	$0.45	$0.47	$53.94 million	$45.65 million	View	N/A
8/13/2014	Q2 2014	($0.06)	($0.08)	$26.02 million	$20.79 million	View	N/A
5/7/2014	Q1 2014	($0.09)	$0.33	$21.18 million	$46.08 million	View	N/A
11/6/2013	Q3 2013	($0.01)	$0.02	$25.52 million	$27.12 million	View	N/A
8/14/2013	Q2 2013	($0.01)	($0.09)	$24.45 million	$24.54 million	View	N/A
5/7/2013	Q1 2013		$0.11		$28.09 million	View	N/A
11/7/2012	Q3 2012	($0.17)	($0.17)			View	N/A
8/15/2012	Q2 2012	($0.32)	$0.03			View	N/A
5/15/2012	Q1 2012	($0.25)	($0.23)			View	N/A
11/2/2011	Q3 2011		($0.04)			View	N/A
5/11/2011	Q1 2011	($0.16)	($0.43)			View	N/A
11/22/2010	Q3 2010		$0.48			View	N/A
8/17/2010	Q2 2010	($0.46)	($0.30)			View	N/A
5/11/2010	Q1 2010	($0.77)	($0.47)			View	N/A
11/10/2009	Q3 2009	($1.17)	($0.44)			View	N/A
8/18/2009	Q2 2009	($1.18)	($0.54)			View	N/A
5/12/2009	Q1 2009	($1.04)	($0.79)			View	N/A
8/27/2008	Q2 2008		($1.38)			View	N/A
5/28/2008	Q1 2008		($0.95)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Genmab As (OTCMKTS:GNMSF) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Genmab As (OTCMKTS GNMSF) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.09%

Insider Trading History for Genmab As (OTCMKTS:GNMSF)

Genmab As (OTCMKTS GNMSF) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Genmab As (OTCMKTS GNMSF) News Headlines

Source:

Date	Headline
	Zacks Investment Research Upgrades Genmab As (GNMSF) to Hold www.americanbankingnews.com - April 19 at 12:28 AM
	Genmab As (GNMSF) Upgraded to "Hold" by ValuEngine www.americanbankingnews.com - April 5 at 1:11 PM
	Analyzing Akebia Therapeutics (AKBA) and Genmab As (GNMSF) www.americanbankingnews.com - April 3 at 3:09 AM
	Genmab As (GNMSF) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - March 31 at 11:09 AM
	Genmab (GNMSF) Presents At Deutsche Bank's Depositary Receipts Virtual Investor Conference - Slideshow seekingalpha.com - March 26 at 3:53 PM
	Jefferies Group Comments on Genmab As' FY2018 Earnings (GNMSF) www.americanbankingnews.com - February 26 at 6:44 AM
	Genmab As (GNMSF) Expected to Earn Q1 2018 Earnings of $0.72 Per Share www.americanbankingnews.com - February 23 at 8:06 AM
	Q4 2017 Earnings Forecast for Genmab As Issued By Jefferies Group (GNMSF) www.americanbankingnews.com - February 7 at 8:18 AM
	Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab) finance.yahoo.com - January 23 at 8:50 AM
	U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma finance.yahoo.com - January 19 at 5:33 PM
	Genmab As (GNMSF) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - January 9 at 11:54 PM
	Analysts Issue Forecasts for Genmab As' FY2018 Earnings (GNMSF) www.americanbankingnews.com - January 8 at 12:06 PM
	ETFs with exposure to Genmab A/S : December 27, 2017 finance.yahoo.com - December 28 at 6:10 AM
	Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017 finance.yahoo.com - December 26 at 9:16 AM
	After Soaring 3,000% in 5 Years, Genmab Tests Stock-Market Habit finance.yahoo.com - December 18 at 5:04 PM
	Genmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial Guidance finance.yahoo.com - November 29 at 5:24 PM
	Genmab A/S (GNMSF) Downgraded by Zacks Investment Research www.americanbankingnews.com - November 26 at 3:34 PM
	Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma finance.yahoo.com - November 21 at 7:08 PM
	Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma finance.yahoo.com - November 21 at 7:08 PM
	Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : November 16, 2017 finance.yahoo.com - November 16 at 2:48 PM
	Major Shareholder Announcement finance.yahoo.com - November 11 at 7:23 AM
	Genmab Announces Financial Results for the First Nine Months of 2017 finance.yahoo.com - November 9 at 6:12 AM
	Genmab A/S – Value Analysis (US OTC:GNMSF) : November 1, 2017 finance.yahoo.com - November 1 at 9:07 PM
	Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 31, 2017 finance.yahoo.com - October 31 at 8:33 PM
	Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017 finance.yahoo.com - October 25 at 2:33 AM
	Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : October 18, 2017 finance.yahoo.com - October 19 at 12:08 AM
	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017 finance.yahoo.com - October 17 at 7:52 PM
	Seattle Genetics initiates mid-stage of tisotumab vedotin in cervical cancer, positive results may support registration seekingalpha.com - October 10 at 9:53 PM
	Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer finance.yahoo.com - October 10 at 4:49 PM
	Genmab A/S (GNMSF) Rating Lowered to Neutral at J P Morgan Chase & Co www.americanbankingnews.com - October 7 at 3:36 PM
$Genmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in Japan$	Genmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in Japan finance.yahoo.com - October 2 at 1:56 PM
	Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017 finance.yahoo.com - September 18 at 6:43 PM
	Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017 finance.yahoo.com - September 12 at 7:58 PM
	Seattle Genetics and Genmab team up to develop ADC tisotumab vedotin seekingalpha.com - August 30 at 9:33 PM
	J&J's Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP alone seekingalpha.com - August 25 at 6:20 AM
	Genmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple Myeloma finance.yahoo.com - August 25 at 6:20 AM
	Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017 finance.yahoo.com - August 23 at 7:38 AM
	Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 21, 2017 finance.yahoo.com - August 21 at 6:32 PM
	Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 10, 2017 finance.yahoo.com - August 11 at 12:47 AM
	Genmab's (GNMSF) CEO Jan van de Winkel on Q2 2017 Results - Earnings Call Transcript seekingalpha.com - August 9 at 7:18 PM
	Genmab Announces Financial Results for the First Half of 2017 finance.yahoo.com - August 9 at 7:18 PM
	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017 finance.yahoo.com - July 18 at 8:51 PM
	Genmab's (GNMSF) CEO Jan van de Winkel on Q1 2017 Results - Earnings Call Transcript www.msn.com - May 11 at 3:41 AM
	Genmab's (GNMSF) CEO Jan van de Winkel on Q4 2016 Results - Earnings Call Transcript seekingalpha.com - February 22 at 10:48 PM
	Genmab Lifts FY16 View For Revenue, Operating Income - Quick Facts - Nasdaq www.nasdaq.com - February 8 at 4:46 AM
	Genmab Lifts FY16 View For Revenue, Operating Income - Quick Facts www.rttnews.com - February 6 at 5:33 PM
	Genmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick Facts - Nasdaq www.nasdaq.com - January 24 at 11:12 PM
	Genmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick Facts www.rttnews.com - January 24 at 6:10 PM
	Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : January 6, 2017 us.rd.yahoo.com - January 6 at 6:03 PM
	Janssen files Darzalex marketing application in Japan for multiple myeloma; $10M milestone due Genmab - Seeking Alpha seekingalpha.com - December 21 at 6:24 PM

Genmab As (OTCMKTS:GNMSF) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Financials are not available for this stock.

Genmab As (OTCMKTS GNMSF) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff